Resmed Inc. (RMD) Shares Soar Above 1-Year High

The stock of Resmed Inc. (NYSE: RMD) has increased by 0.91 when compared to last closing price of 184.36. Despite this, the company has experienced a -4.19% fall in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-02 that Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, RMD, ZBH, PODD and LNTH are well-poised to gain from the favorable factors.

Is It Worth Investing in Resmed Inc. (NYSE: RMD) Right Now?

Resmed Inc. (NYSE: RMD) has a higher price-to-earnings ratio of 30.82x compared to its average ratio, The 36-month beta value for RMD is at 0.68. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 as “hold,” and 3 as “sell.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


The public float for RMD is 145.92M, and currently, shorts hold a 5.25% of that float. The average trading volume for RMD on April 04, 2024 was 1.00M shares.

RMD’s Market Performance

The stock of Resmed Inc. (RMD) has seen a -4.19% decrease in the past week, with a 2.94% rise in the past month, and a 8.30% gain in the past quarter. The volatility ratio for the week is 2.48%, and the volatility levels for the past 30 days are at 2.19% for RMD. The simple moving average for the past 20 days is -2.56% for RMD’s stock, with a 6.30% simple moving average for the past 200 days.

Analysts’ Opinion of RMD

Many brokerage firms have already submitted their reports for RMD stocks, with KeyBanc Capital Markets repeating the rating for RMD by listing it as a “Overweight.” The predicted price for RMD in the upcoming period, according to KeyBanc Capital Markets is $227 based on the research report published on February 06, 2024 of the current year 2024.

Morgan Stanley, on the other hand, stated in their research note that they expect to see RMD reach a price target of $169, previously predicting the price at $180. The rating they have provided for RMD stocks is “Overweight” according to the report published on October 27th, 2023.

RBC Capital Mkts gave a rating of “Sector Perform” to RMD, setting the target price at $202 in the report published on October 12th of the previous year.

RMD Trading at -0.12% from the 50-Day Moving Average

After a stumble in the market that brought RMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.60% of loss for the given period.

Volatility was left at 2.19%, however, over the last 30 days, the volatility rate increased by 2.48%, as shares surge +4.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.21% upper at present.

During the last 5 trading sessions, RMD fell by -4.19%, which changed the moving average for the period of 200-days by -15.04% in comparison to the 20-day moving average, which settled at $191.34. In addition, Resmed Inc. saw 8.15% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at RMD starting from Rider Michael J, who sale 81 shares at the price of $180.00 back on Mar 04 ’24. After this action, Rider Michael J now owns 6,607 shares of Resmed Inc., valued at $14,580 using the latest closing price.

Rider Michael J, the Global General Counsel of Resmed Inc., sale 200 shares at $173.25 during a trade that took place back on Mar 01 ’24, which means that Rider Michael J is holding 6,688 shares at $34,650 based on the most recent closing price.

Stock Fundamentals for RMD

Current profitability levels for the company are sitting at:

  • 0.26 for the present operating margin
  • 0.57 for the gross margin

The net margin for Resmed Inc. stands at 0.2. The total capital return value is set at 0.19. Equity return is now at value 21.66, with 13.11 for asset returns.

Based on Resmed Inc. (RMD), the company’s capital structure generated 0.24 points at debt to capital in total, while cash flow to debt ratio is standing at 0.78. The debt to equity ratio resting at 0.31. The interest coverage ratio of the stock is -19.43.

Currently, EBITDA for the company is 1.34 billion with net debt to EBITDA at 0.83. When we switch over and look at the enterprise to sales, we see a ratio of 6.54. The receivables turnover for the company is 5.98for trailing twelve months and the total asset turnover is 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.11.


In conclusion, Resmed Inc. (RMD) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts